Navigation Links
Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show
Date:10/6/2010

ISTANBUL, Oct. 7 /PRNewswire/ -- Privigen®, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

In a separate observational study, patients reported higher overall satisfaction with Privigen compared to previous treatments, along with fewer adverse events and improvements in quality of life. Even at higher rates of infusion, Privigen tolerability appeared superior to Sandoglobulin.

"Some patients have difficulty tolerating infusions at high rates, experiencing side effects such as general tiredness and long-lasting headaches," said Bodo Grimbacher, MD, Professor, Division of Immunology, Royal Free Hospital NHS Trust, London, and study investigator. "Our observation suggests that Privigen allows for higher infusion rates, substantially reducing the time needed for infusions."

Privigen is approved in the European Union, Switzerland, Canada and the United States for treating patients diagnosed with primary immune deficiency (PID) and immune thrombocytopenic purpura (ITP). In Europe, Privigen is also approved for treating Guillain-Barre Syndrome and Kawasaki-Syndrome.

Study DesignIn an interim analysis of an ongoing, multicenter, observational study to evaluate the efficacy and tolerability of Privigen, 76 patients received a total of 371 Privigen infusions. Overall, infection incidence decreased following initiation of treatment with Privigen compared with 6 months prior to the study (37 infections versus 160 infections). Patients who had not received any IVIg treatment for 6 months prior to study entry, and who received Privigen for at least 3 months, experienced significantly fewer infections during the study period than before study entry. Efficacy and tolerability were judged as very good or good in 91 percent and 88 percent of patients, respectively. Adverse events were reported for 17 of the 371 infusions.

Findings from a second observational study examined 35 patients receiving intravenous replacement therapy who were switched from Sandoglobulin® NF liquid (12% IgG) to Privigen without dose adjustment. Results indicate that a large proportion of patients could not tolerate infusion at rates higher than 0.5 mL/kg/h with Sandoglobulin, due to side effects. In contrast, some patients were also able to infuse Privigen safely at an infusion rate of 7.2 mL/kg/h for more than 30 minutes, without compromising tolerability. Approximately 70 percent of patients were able to infuse higher rates with Privigen, substantially reducing the time for infusion. Anecdotal feedback also indicated that patients experienced fewer adverse events, reported improvements in their quality of life and reported higher overall satisfaction following a switch to Privigen.

About Privigen Privigen is the first and only 10 percent liquid IVIg stabilized with L-proline, a naturally occurring amino-acid. Privigen is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin, in patients with hyperprolinemia, and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. In clinical studies, the most common adverse reactions with Privigen were headache, pain, nausea, pyrexia/ hyperthermia, fatigue, chills and anemia.

About Primary ImmunodeficienciesPrimary immunodeficiencies (PIs) are a group of more than 150 diseases that affect the cells, tissues and proteins of the immune system. In people with PI, the immune system is either absent or functioning inadequately, leaving them more susceptible to infection. For individuals with PI – many of them children – infections may not improve with treatment as expected, and may keep returning. As a result, patients may face repeated rounds of antibiotics or be hospitalized for treatment. Repeated infections can lead to organ damage, which, over time, can become life-threatening. Collectively, PIs affect an estimated 10 million people worldwide, and the incidence is estimated to be 1 in 10,000.

About CSL BehringCSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com. Contact:Sheila A. Burke, Director, Communications & Public RelationsWorldwide Commercial OperationsCSL BehringC: 484-919-2618O: 610-878-4209Sheila.Burke@cslbehring.com
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ethicon Endo-Surgery Demonstrates Commitment to Innovation and Surgeon Choice at the American College of Surgeons Conference (ACS)
2. Peptimmune Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone
3. Boston Scientifics TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
4. BCM-95 Demonstrates Superior Anti-Inflammatory Effects
5. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
6. Kaiser Permanente Demonstrates Success of Large-Scale Total Joint Replacement Registry
7. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
8. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
9. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
10. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
11. Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):